171 related articles for article (PubMed ID: 34644414)
1. Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
Chow EJ; Aplenc R; Vrooman LM; Doody DR; Huang YV; Aggarwal S; Armenian SH; Baker KS; Bhatia S; Constine LS; Freyer DR; Kopp LM; Leisenring WM; Asselin BL; Schwartz CL; Lipshultz SE
Cancer; 2022 Feb; 128(4):788-796. PubMed ID: 34644414
[TBL] [Abstract][Full Text] [Related]
2. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.
Chow EJ; Asselin BL; Schwartz CL; Doody DR; Leisenring WM; Aggarwal S; Baker KS; Bhatia S; Constine LS; Freyer DR; Lipshultz SE; Armenian SH
J Clin Oncol; 2015 Aug; 33(24):2639-45. PubMed ID: 26014292
[TBL] [Abstract][Full Text] [Related]
3. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
Chow EJ; Aggarwal S; Doody DR; Aplenc R; Armenian SH; Baker KS; Bhatia S; Blythe N; Colan SD; Constine LS; Freyer DR; Kopp LM; Laverdière C; Leisenring WM; Sasaki N; Vrooman LM; Asselin BL; Schwartz CL; Lipshultz SE
J Clin Oncol; 2023 Apr; 41(12):2248-2257. PubMed ID: 36669148
[TBL] [Abstract][Full Text] [Related]
4. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.
Lo AC; Liu A; Liu Q; Yasui Y; Castellino SM; Kelly KM; Hererra AF; Friedberg JW; Friedman DL; Schwartz CL; Pei Q; Kessel S; Bergeron-Gravel S; Dama H; Roberts K; Constine LS; Hodgson DC
JAMA Netw Open; 2024 Jan; 7(1):e2351062. PubMed ID: 38241048
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
[TBL] [Abstract][Full Text] [Related]
6. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
7. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
Barry EV; Vrooman LM; Dahlberg SE; Neuberg DS; Asselin BL; Athale UH; Clavell LA; Larsen EC; Moghrabi A; Samson Y; Schorin MA; Cohen HJ; Lipshultz SE; Sallan SE; Silverman LB
J Clin Oncol; 2008 Mar; 26(7):1106-11. PubMed ID: 18309945
[TBL] [Abstract][Full Text] [Related]
8. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
Lipshultz SE; Anderson LM; Miller TL; Gerschenson M; Stevenson KE; Neuberg DS; Franco VI; LiButti DE; Silverman LB; Vrooman LM; Sallan SE;
Cancer; 2016 Mar; 122(6):946-53. PubMed ID: 26762648
[TBL] [Abstract][Full Text] [Related]
9. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
Vrooman LM; Neuberg DS; Stevenson KE; Asselin BL; Athale UH; Clavell L; Cole PD; Kelly KM; Larsen EC; Laverdière C; Michon B; Schorin M; Schwartz CL; Cohen HJ; Lipshultz SE; Silverman LB; Sallan SE
Eur J Cancer; 2011 Jun; 47(9):1373-9. PubMed ID: 21514146
[TBL] [Abstract][Full Text] [Related]
10. Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
Lapointe MO; Caru M; Curnier D; Raboisson MJ; Andelfinger G; Krajinovic M; Laverdière C; Sinnett D; Périé D
J Pediatr Hematol Oncol; 2023 Mar; 45(2):70-77. PubMed ID: 36161876
[TBL] [Abstract][Full Text] [Related]
11. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
12. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
Schwartz CL; Wexler LH; Krailo MD; Teot LA; Devidas M; Steinherz LJ; Goorin AM; Gebhardt MC; Healey JH; Sato JK; Meyers PA; Grier HE; Bernstein ML; Lipshultz SE
Pediatr Blood Cancer; 2016 Jan; 63(1):54-61. PubMed ID: 26398490
[TBL] [Abstract][Full Text] [Related]
13. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group.
Kopp LM; Womer RB; Schwartz CL; Ebb DH; Franco VI; Hall D; Barkauskas DA; Krailo MD; Grier HE; Meyers PA; Wexler LH; Marina NM; Janeway KA; Gorlick R; Bernstein ML; Lipshultz SE;
Cardiooncology; 2019; 5():15. PubMed ID: 32154021
[TBL] [Abstract][Full Text] [Related]
14. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
15. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
Lipshultz SE; Miller TL; Lipsitz SR; Neuberg DS; Dahlberg SE; Colan SD; Silverman LB; Henkel JM; Franco VI; Cushman LL; Asselin BL; Clavell LA; Athale U; Michon B; Laverdière C; Schorin MA; Larsen E; Usmani N; Sallan SE;
Pediatrics; 2012 Dec; 130(6):1003-11. PubMed ID: 23166343
[TBL] [Abstract][Full Text] [Related]
16. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.
Moghrabi A; Levy DE; Asselin B; Barr R; Clavell L; Hurwitz C; Samson Y; Schorin M; Dalton VK; Lipshultz SE; Neuberg DS; Gelber RD; Cohen HJ; Sallan SE; Silverman LB
Blood; 2007 Feb; 109(3):896-904. PubMed ID: 17003366
[TBL] [Abstract][Full Text] [Related]
17. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
18. Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group.
Lipshultz ER; Chow EJ; Doody DR; Armenian SH; Asselin BL; Baker KS; Bhatia S; Constine LS; Freyer DR; Kopp LM; Schwartz CL; Lipshultz SE; Vrooman LM
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):536-542. PubMed ID: 34810210
[TBL] [Abstract][Full Text] [Related]
19. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Choi HS; Park ES; Kang HJ; Shin HY; Noh CI; Yun YS; Ahn HS; Choi JY
J Korean Med Sci; 2010 Sep; 25(9):1336-42. PubMed ID: 20808678
[TBL] [Abstract][Full Text] [Related]
20. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort.
Gibson TM; Mostoufi-Moab S; Stratton KL; Leisenring WM; Barnea D; Chow EJ; Donaldson SS; Howell RM; Hudson MM; Mahajan A; Nathan PC; Ness KK; Sklar CA; Tonorezos ES; Weldon CB; Wells EM; Yasui Y; Armstrong GT; Robison LL; Oeffinger KC
Lancet Oncol; 2018 Dec; 19(12):1590-1601. PubMed ID: 30416076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
